FOR IMMEDIATE RELEASE Contact Information: Robert Siegfried VP, Finance and Administration 952.912.5400   More News   ( ‹ back to main article) November 14, 2007 Advanced Bio-Surfaces Announces New CEO November 6, 2007 The OrthoGlide® Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement June 07, 2007 OrthoGlide® Medial Knee Implant Reports Over 200 Implants April 11, 2007 Advanced Bio-Surfaces® Receives Award for OrthoGlide® Medial Knee Implant May 25, 2006 Advanced Bio-Surfaces® Announces Initial Experiences of OrthoGlide® Medial Knee Implant February 15, 2006 Advanced Bio-Surfaces® Receives CE Mark for OrthoGlide® Medial Knee Implant February 8, 2006 Advanced Bio-Surfaces® Receives FDA Clearance to Market for OrthoGlide® Medial Knee Implant

The OrthoGlide® Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement Over 300 implants reported in the intended patient population for company’s minimally invasive knee implant. MINNEAPOLIS, November 6, 2007/PRNewswire/ -- Advanced Bio-Surfaces, Inc., (ABS) an orthopedic implant developer and manufacturer, announced today the OrthoGlide Medial Knee Implant has been implanted in more than 300 patients in the USA. The OrthoGlide implant is a minimally invasive device intended to relieve pain caused by moderate osteoarthritis of the knee. “The interest from surgeons and patients for a minimally invasive alternative to the current knee replacement options on the market continues to expand” said Dr. Jeff Felt, Chairman of Advanced Bio-Surfaces. “We have increased the number of training sites in the United States in an effort to accommodate the number of interested surgeons. As the surgeon community learns more about the product and its minimal surgical approach, they understand the need for the OrthoGlide implant as a viable option for some patients. The growth is inspired by surgeons who want to be trained on a procedure that can be positioned as an alternative to total knee replacement.” In addition to training and supporting the orthopedic surgeon community interested in the OrthoGlide implant, ABS is also involved in a clinical study. This week, during the American College of Rheumatology’s annual meeting in Boston, MA, William Arnold, M.D. will present data from the study that supports the OrthoGlide’s clinical effectiveness. The presentation will be held in Room 153 of the Boston Convention and Exhibit Center at 5:30 p.m. on Saturday, November 10th. About Advanced Bio-Surfaces, Inc. ABS is a privately held company dedicated to the development of innovative joint restoration products. The company’s first product, the OrthoGlide Medial Knee Implant, is intended for the treatment of patients with moderate osteoarthritis of the medial compartment. The company received 510(k) clearance to market from the U.S. Food and Drug Administration (FDA) and CE mark notification from its Notified Body, in February 2006. For additional information contact ABS at 952.912.5400.